PGR and neoplasm: Clinical decision making regarding adjuvant systemic therapy may vary and is commonly influenced by patient, clinical and pathologic factors, including tumor size, histologic grade, lymph node status and ER, PR and HER2 expression, all of which have been shown to significantly influence the risk of disease recurrence [3].